NewAmsterdam Pharma Co N.V.
NAMS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001936258
In the last 90 days, NewAmsterdam Pharma Co N.V. insiders filed 1 open-market purchase and 3 sales; 194 institutions reported holding it in 13F filings for Q2 2026, worth $4.13B in total; 3 superinvestors hold it, including Viking Global Investors and Maverick Capital.
Other share classesNAMSW
13F holders, Q4 2023
Institutional positions in NewAmsterdam Pharma Co N.V. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 32
- −3 vs. Q3 2023
- Shares held
- 61.9M
- +11.7M (+23.4%) vs. Q3 2023
- Total value
- $691.4M
- +$227.3M (+49.0%) vs. Q3 2023
- New holders
- 4
- 9 more added
- Sold out
- 7
- 5 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NAMS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 194 | $4.13B |
| Q1 2026 | 171 | $3.96B |
| Q4 2025 | 187 | $4.19B |
| Q3 2025 | 137 | $3.43B |
| Q2 2025 | 131 | $2.11B |
| Q1 2025 | 126 | $2.28B |
| Q4 2024 | 131 | $2.53B |
| Q3 2024 | 100 | $1.28B |
| Q2 2024 | 90 | $1.38B |
| Q1 2024 | 76 | $1.71B |
| Q4 2023 | 32 | $691.4M |
| Q3 2023 | 35 | $464.1M |
| Q2 2023 | 29 | $580.6M |
| Q1 2023 | 19 | $444.9M |
| Q4 2022 | 14 | $362.2M |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding NewAmsterdam Pharma Co N.V.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 12,131,705 | $135.5M | 7.25% | 00.0% | Unchanged |
| FCPM III Services B.V. | 11,831,461 | $132.2M | 38.94% | +11,831,461 | New |
| Bain Capital Life Sciences Investors, LLC | 10,473,913 | $117.0M | 11.21% | 00.0% | Unchanged |
| Viking Global Investors LPSuperinvestorViking Global Investors | 8,024,565 | $89.6M | 0.33% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 7,864,000 | $87.8M | 1.37% | −1,136,000−12.6% | Reduced |
| Medicxi Ventures Management (Jersey) Ltd | 2,869,565 | $32.1M | 10.82% | 00.0% | Unchanged |
| BVF Inc | 1,521,948 | $17.0M | 0.43% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 1,384,321 | $15.5M | 0.00% | +1,384,321 | New |
| GMT Capital Corp | 1,383,800 | $15.5M | 0.58% | 00.0% | Unchanged |
| Millennium Management LLC | 1,326,103 | $14.8M | 0.01% | +281,319+26.9% | Added |
| Adage Capital Partners GP, L.L.C. | 1,300,000 | $14.5M | 0.03% | +100,000+8.3% | Added |
| Eversept Partners, LP | 374,404 | $4.18M | 0.41% | −286,214−43.3% | Reduced |
| Parkman Healthcare Partners LLC | 300,750 | $3.36M | 0.48% | +51,726+20.8% | Added |
| AXA S.A. | 276,328 | $3.09M | 0.01% | −6,687−2.4% | Reduced |
| Opaleye Management Inc. | 265,388 | $2.96M | 0.80% | +265,388 | New |
| Ensign Peak Advisors, Inc | 191,956 | $2.14M | 0.00% | −245,777−56.1% | Reduced |
| Affinity Asset Advisors, LLC | 125,000 | $1.40M | 0.28% | 00.0% | Unchanged |
| Schonfeld Strategic Advisors LLC | 66,900 | $747.3K | 0.01% | +2,200+3.4% | Added |
| Geode Capital Management, LLC | 47,324 | $528.6K | 0.00% | +5,516+13.2% | Added |
| Marshall Wace, LLP | 33,941 | $379.1K | 0.00% | +23,777+233.9% | Added |
| Morgan Stanley | 28,538 | $318.8K | 0.00% | +26,836+1,576.7% | Added |
| BlackRock Inc. | 22,941 | $256.3K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 21,046 | $235.1K | 0.00% | −10,351−33.0% | Reduced |
| Royal Bank of Canada | 10,875 | $121.0K | 0.00% | +9,875+987.5% | Added |
| Venture Visionary Partners LLC | 10,000 | $111.7K | 0.01% | 00.0% | Unchanged |
| Wolverine Asset Management LLC | 8,694 | $97.1K | 0.00% | +5,769+197.2% | Added |
| UBS Group AG | 800 | $8.94K | 0.00% | +800 | New |
| Barclays PLC | 513 | $5.73K | 0.00% | 00.0% | Unchanged |
| Cutler Group LP | 500 | $5.00K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 300 | $3.35K | 0.00% | 00.0% | Unchanged |
| Atticus Wealth Management, LLC | 100 | $1.12K | 0.00% | 00.0% | Unchanged |
| DuPont Capital Management Corp | 1 | $11 | 0.00% | 00.0% | Unchanged |
| Janus Henderson Group PLC | 0 | $0 | 0.00% | −434,912−100.0% | Sold out |
| UBS Oconnor LLC | 0 | $0 | 0.00% | −45,000−100.0% | Sold out |
| Alyeska Investment Group, L.P. | 0 | $0 | 0.00% | −44,432−100.0% | Sold out |
| Maven Securities LTD | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| Parkwood LLC | 0 | $0 | 0.00% | −20,209−100.0% | Sold out |
| CIBC Private Wealth Group, LLC | 0 | $0 | 0.00% | −13,000−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −2,622−100.0% | Sold out |